Abstract
During the past few years, a group of cyclopenta[b]benzofurans from the plant genus Aglaia has received broad scientific attention as interesting natural product lead compounds with potential anticancer and insecticidal activities. Since the first cyclopenta[b]benzofuran derivative, rocaglamide, from Aglaia elliptifolia, was found to exhibit antileukemic activity in a murine in vivo model, the genus Aglaia has been subjected to further investigation. Over 40 cyclopenta [b]benzofurans have been tested against different human cancer cell lines, and the cumulative results provide some important clues as to how to improve their activity through modification of their chemical structures. The semisynthesis and total synthesis of the cyclopenta [b]benzofurans have been conducted. Although the ultimate molecular target(s) responsible for their antiproliferative activity has not yet been identified, studies on their cellular mechanism of action have demonstrated that some of these compounds inhibit TNF-α or PMA-induced NF-κB activity in T-lymphocytes and induce apoptosis in different human cancer cell lines. Based on the published data thus far, cyclopenta[b]benzofurans offer excellent potential as therapeutic agent candidates in cancer chemotherapy, even if much work still remains to be done for their further development.
Keywords: Aglaia, Meliaceae, flavaglines, cyclopenta[b]benzofurans, cyclopenta[bc]benzopyrans, benzo[b]oxepines, antiproliferative agents, murine in vivo test systems
Anti-Cancer Agents in Medicinal Chemistry
Title: Potential of Cyclopenta[b]benzofurans from Aglaia Species in Cancer Chemotherapy
Volume: 6 Issue: 4
Author(s): Soyoung Kim, Angela A. Salim, Steven M. Swanson and A. Douglas Kinghorn
Affiliation:
Keywords: Aglaia, Meliaceae, flavaglines, cyclopenta[b]benzofurans, cyclopenta[bc]benzopyrans, benzo[b]oxepines, antiproliferative agents, murine in vivo test systems
Abstract: During the past few years, a group of cyclopenta[b]benzofurans from the plant genus Aglaia has received broad scientific attention as interesting natural product lead compounds with potential anticancer and insecticidal activities. Since the first cyclopenta[b]benzofuran derivative, rocaglamide, from Aglaia elliptifolia, was found to exhibit antileukemic activity in a murine in vivo model, the genus Aglaia has been subjected to further investigation. Over 40 cyclopenta [b]benzofurans have been tested against different human cancer cell lines, and the cumulative results provide some important clues as to how to improve their activity through modification of their chemical structures. The semisynthesis and total synthesis of the cyclopenta [b]benzofurans have been conducted. Although the ultimate molecular target(s) responsible for their antiproliferative activity has not yet been identified, studies on their cellular mechanism of action have demonstrated that some of these compounds inhibit TNF-α or PMA-induced NF-κB activity in T-lymphocytes and induce apoptosis in different human cancer cell lines. Based on the published data thus far, cyclopenta[b]benzofurans offer excellent potential as therapeutic agent candidates in cancer chemotherapy, even if much work still remains to be done for their further development.
Export Options
About this article
Cite this article as:
Kim Soyoung, Salim A. Angela, Swanson M. Steven and Douglas Kinghorn A., Potential of Cyclopenta[b]benzofurans from Aglaia Species in Cancer Chemotherapy, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/187152006777698123
DOI https://dx.doi.org/10.2174/187152006777698123 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Stem Cell Therapy in Chronic Obstructive Pulmonary Disease. Seeking the Prometheus Effect
Current Drug Targets Modulation of Toll-Like Receptor 4. Insights from X-Ray Crystallography and Molecular Modeling
Current Topics in Medicinal Chemistry Thioguanine, Mercaptopurine: Their Analogs and Nucleosides as Antimetabolites
Current Pharmaceutical Design Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress
Current Drug Targets Identification of Two Novel Mutations in the <i>ATM</i> Gene from Patients with Ataxia-Telangiectasia by Whole Exome Sequencing
Current Genomics Meet our Editorial Board Member
Current Cancer Therapy Reviews Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Protein & Peptide Letters Cyclin Dependent Kinase as Significant Target for Cancer Treatment
Current Cancer Therapy Reviews Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Pharmaceutical Nanotechnology Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Meet Our Editorial Board Member
Current Cancer Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chemical Modifications of Two Polysaccharides as Drug Carriers
Current Organic Synthesis Preface:
Current Molecular Pharmacology Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms
Current Cancer Drug Targets